Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units : a prospective observational study
Coronavirus disease 2019 (COVID-19) increases the risk of coagulopathy. Although the presence of antiphospholipid antibodies (aPLs) has been proposed as a possible mechanism of COVID-19-induced coagulopathy, its clinical significance remains uncertain. Therefore, this study aimed to evaluate the prevalence and clinical significance of aPLs among critically ill patients with COVID-19. This prospective observational study included 60 patients with COVID-19 admitted to intensive care units (ICU). The study outcomes included prevalence of aPLs, and a primary composite outcome of all-cause mortality and arterial or venous thrombosis between antiphospholipid-positive and antiphospholipid-negative patients during their ICU stay. Multiple logistic regression was used to assess the influence of aPLs on the primary composite outcome of mortality and thrombosis. A total of 60 critically ill patients were enrolled. Among them, 57 (95%) were men, with a mean age of 52.8 ± 12.2 years, and the majority were from Asia (68%). Twenty-two patients (37%) were found be antiphospholipid-positive; 21 of them were positive for lupus anticoagulant, whereas one patient was positive for anti-β2-glycoprotein IgG/IgM. The composite outcome of mortality and thrombosis during their ICU stay did not differ between antiphospholipid-positive and antiphospholipid-negative patients (4 [18%] vs. 6 [16%], adjusted odds ratio 0.98, 95% confidence interval 0.1-6.7; p value = 0.986). The presence of aPLs does not seem to affect the outcomes of critically ill patients with COVID-19 in terms of all-cause mortality and thrombosis. Therefore, clinicians may not screen critically ill patients with COVID-19 for aPLs unless deemed clinically appropriate.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Rheumatology international - 41(2021), 7 vom: 26. Juli, Seite 1243-1252 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Najim, Mostafa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 07.06.2021 Date Revised 15.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00296-021-04875-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM325069697 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM325069697 | ||
| 003 | DE-627 | ||
| 005 | 20231225191645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00296-021-04875-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1083.xml |
| 035 | |a (DE-627)NLM325069697 | ||
| 035 | |a (NLM)33954813 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Najim, Mostafa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units |b a prospective observational study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.06.2021 | ||
| 500 | |a Date Revised 15.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) increases the risk of coagulopathy. Although the presence of antiphospholipid antibodies (aPLs) has been proposed as a possible mechanism of COVID-19-induced coagulopathy, its clinical significance remains uncertain. Therefore, this study aimed to evaluate the prevalence and clinical significance of aPLs among critically ill patients with COVID-19. This prospective observational study included 60 patients with COVID-19 admitted to intensive care units (ICU). The study outcomes included prevalence of aPLs, and a primary composite outcome of all-cause mortality and arterial or venous thrombosis between antiphospholipid-positive and antiphospholipid-negative patients during their ICU stay. Multiple logistic regression was used to assess the influence of aPLs on the primary composite outcome of mortality and thrombosis. A total of 60 critically ill patients were enrolled. Among them, 57 (95%) were men, with a mean age of 52.8 ± 12.2 years, and the majority were from Asia (68%). Twenty-two patients (37%) were found be antiphospholipid-positive; 21 of them were positive for lupus anticoagulant, whereas one patient was positive for anti-β2-glycoprotein IgG/IgM. The composite outcome of mortality and thrombosis during their ICU stay did not differ between antiphospholipid-positive and antiphospholipid-negative patients (4 [18%] vs. 6 [16%], adjusted odds ratio 0.98, 95% confidence interval 0.1-6.7; p value = 0.986). The presence of aPLs does not seem to affect the outcomes of critically ill patients with COVID-19 in terms of all-cause mortality and thrombosis. Therefore, clinicians may not screen critically ill patients with COVID-19 for aPLs unless deemed clinically appropriate | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Antiphospholipid antibodies | |
| 650 | 4 | |a Arterial thrombosis | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coagulopathy | |
| 650 | 4 | |a Critically ill patients | |
| 650 | 4 | |a Venous thrombosis | |
| 650 | 7 | |a Antibodies, Antiphospholipid |2 NLM | |
| 650 | 7 | |a C-Reactive Protein |2 NLM | |
| 650 | 7 | |a 9007-41-4 |2 NLM | |
| 700 | 1 | |a Rahhal, Alaa |e verfasserin |4 aut | |
| 700 | 1 | |a Khir, Fadi |e verfasserin |4 aut | |
| 700 | 1 | |a Aljundi, Amer Hussien |e verfasserin |4 aut | |
| 700 | 1 | |a Abu Yousef, Safae |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Feryal |e verfasserin |4 aut | |
| 700 | 1 | |a Amer, Aliaa |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Ahmed S |e verfasserin |4 aut | |
| 700 | 1 | |a Saleh, Samira |e verfasserin |4 aut | |
| 700 | 1 | |a Alfaridi, Dekra |e verfasserin |4 aut | |
| 700 | 1 | |a Mahfouz, Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Alyafei, Sumaya |e verfasserin |4 aut | |
| 700 | 1 | |a Howady, Faraj |e verfasserin |4 aut | |
| 700 | 1 | |a Khatib, Mohamad |e verfasserin |4 aut | |
| 700 | 1 | |a Alemadi, Samar A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d 1985 |g 41(2021), 7 vom: 26. Juli, Seite 1243-1252 |w (DE-627)NLM012644315 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2021 |g number:7 |g day:26 |g month:07 |g pages:1243-1252 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00296-021-04875-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2021 |e 7 |b 26 |c 07 |h 1243-1252 | ||